Last reviewed · How we verify
Jenzyl (RIDAFOROLIMUS)
Jenzyl (generic name: RIDAFOROLIMUS) is a ridaforolimus drug. It is currently in discontinued development.
Jenzyl blocks the mTOR pathway, which is a key regulator of cell growth and division.
Jenzyl, also known as Ridaforolimus, is a small molecule inhibitor of the serine/threonine-protein kinase mTOR. It is classified as an inhibitor and targets the mTOR molecular pathway.
At a glance
| Generic name | RIDAFOROLIMUS |
|---|---|
| Drug class | ridaforolimus |
| Target | Dual specificity tyrosine-phosphorylation-regulated kinase 1B, Serine/threonine-protein kinase mTOR |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Mechanism of action
Think of the mTOR pathway like a traffic light for cell growth. When mTOR is active, it's like the light is green, and the cell can grow and divide. Jenzyl works by flipping the light to red, stopping the cell from growing and dividing out of control.
Approved indications
Common side effects
Key clinical trials
- IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System (NA)
- First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease (NA)
- IonMAN Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System (NA)
- BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) in Coronary Stenosis Trial
- Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED) (PHASE1)
- Study of BioNIR Drug Eluting Stent System in Coronary Stenosis (NA)
- MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (NA)
- Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jenzyl CI brief — competitive landscape report
- Jenzyl updates RSS · CI watch RSS
Frequently asked questions about Jenzyl
What is Jenzyl?
How does Jenzyl work?
What is the generic name of Jenzyl?
What drug class is Jenzyl in?
What development phase is Jenzyl in?
What does Jenzyl target?
Related
- Drug class: All ridaforolimus drugs
- Target: All drugs targeting Dual specificity tyrosine-phosphorylation-regulated kinase 1B, Serine/threonine-protein kinase mTOR
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing